Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Athersys, Inc. is a biotechnology company focused on developing regenerative medicine therapies, particularly its MultiStem cell therapy platform, which targets conditions such as stroke and traumatic brain injury. The company's unique competitive advantage lies in its proprietary technology that enables the use of allogeneic stem cells, which can be administered without the need for matching donor cells, thus broadening the potential patient base.
Athersys generates revenue primarily through licensing agreements for its MultiStem technology, which allows for the development of therapies by partners. The company has no current product sales but aims to monetize its technology through strategic collaborations and partnerships.
Progress in clinical trials for MultiStem therapy, particularly for stroke and traumatic brain injury
Partnership announcements or licensing deals with larger pharmaceutical companies
Regulatory approvals or setbacks from the FDA
Market sentiment regarding the biotechnology sector as a whole
Regulatory changes that could impact the approval process for new therapies
Technological disruption from competing regenerative medicine technologies
Emergence of alternative therapies that could outperform MultiStem
Increased competition from larger biotech firms with more resources
High cash burn rate leading to potential liquidity issues
Dependence on successful fundraising to support ongoing operations
low - The demand for biotechnology products is less sensitive to economic cycles compared to other sectors, as healthcare needs persist regardless of economic conditions.
Moderate - Rising interest rates can increase the cost of capital for biotech firms, potentially impacting funding for R&D and clinical trials.
minimal - Athersys has a negative debt/equity ratio, indicating limited reliance on debt financing.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has experienced significant volatility, particularly with recent returns showing a decline of 99.2% over the past year.